Bicameral Congressional Letter Demands Transparency from FDA

Charles A. “Chuck” Donovan | April 26, 2016

Yesterday 75 members of Congress, led by Rep. Chris Smith of New Jersey and Sen. James Lankford of Oklahoma, sent a letter to the Commissioner of the Food and Drug Administration demanding answers to questions about the FDA’s surprise approval of relaxed protocols for the distribution of the abortion-inducing drug regimen known as Mifeprex. The changes, announced on March 30, significantly increase the duration of pregnancy at which the drug regimen may be administered, raising it from 49 days (7 weeks) from the last menstrual period (LMP) to 70 days (10 weeks) post-LMP.

Medication Abortion: FDA Guidelines and Personal Experience

Genevieve Plaster, M.A. | April 7, 2016

Last week, the Food and Drug Administration (FDA) changed the regulations for RU-486, the “abortion pill,” allowing its use up to 70 days into pregnancy, three weeks past the previous guidelines. On the same day, Abby Johnson’s The Walls Are Talking: Former Abortion Clinic Workers Tell Their Stories, was officially released. One chapter in particular stood out as especially timely in regards to the news: “Medication Abortion.”